公开(公告)号：US20210177837A1

公开(公告)日：2021-06-17

申请号：US17046528

申请日：2019-04-11

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Andrew COOK ,  Dominic REYNOLDS ,  Cheng ZHONG ,  Ryan BRAWN ,  Shelby ELLERY ,  Thiwanka SAMARAKOON ,  Xiang LIU ,  Sudeep PRAJAPATI ,  Megan SHEEHAN ,  Jason T. LOWE ,  James PALACINO

IPC: A61K31/496 ,  A61K9/00 ,  A61K39/395 ,  A61K38/21 ,  A61K38/20 ,  A61K38/19 ,  C07D313/00 ,  C07D405/06 ,  C07D405/10 ,  C07D405/12 ,  C07D413/14 ,  C07D498/08 ,  C07D491/107 ,  C07D407/12 ,  C07D417/10 ,  C07D413/10 ,  C07D487/04 ,  C07D453/02 ,  C07D405/14 ,  C07D413/12 ,  C07D409/12 ,  C07D471/10 ,  A61K31/5377 ,  A61K31/497 ,  A61K31/541 ,  A61K31/506 ,  A61K31/551 ,  A61K31/5386 ,  A61P35/00

Abstract: The present disclosure provides pladienolide compounds, pharmaceutical compositions containing such compounds, and pladienolide compounds for use in methods of medical treatment. These compounds may be useful in the treatment of cancer, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are pladienolide compounds for use in methods of treating cancers by administering at least one pladienolide compound disclosed herein and at least one additional therapy.

公开(公告)号：US20230301990A1

公开(公告)日：2023-09-28

申请号：US18180063

申请日：2023-03-07

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Andrew COOK ,  Dominic REYNOLDS ,  Cheng ZHONG ,  Ryan BRAWN ,  Shelby ELLERY ,  Thiwanka SAMARAKOON ,  Xiang LIU ,  Sudeep PRAJAPATI ,  Megan SHEEHAN ,  Jason T. LOWE ,  James PALACINO

IPC: A61K31/496 ,  A61P35/00 ,  A61K9/00 ,  A61K31/497 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/541 ,  A61K31/551 ,  A61K38/19 ,  A61K38/20 ,  A61K38/21 ,  A61K39/395 ,  C07D313/00 ,  C07D405/06 ,  C07D405/10 ,  C07D405/12 ,  C07D405/14 ,  C07D407/12 ,  C07D409/12 ,  C07D413/10 ,  C07D413/12 ,  C07D413/14 ,  C07D417/10 ,  C07D453/02 ,  C07D471/10 ,  C07D487/04 ,  C07D491/107 ,  C07D498/08

CPC classification number: A61K31/496 ,  A61P35/00 ,  A61K9/0053 ,  A61K31/497 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/541 ,  A61K31/551 ,  A61K38/191 ,  A61K38/2013 ,  A61K38/2066 ,  A61K38/208 ,  A61K38/2086 ,  A61K38/217 ,  A61K39/3955 ,  C07D313/00 ,  C07D405/06 ,  C07D405/10 ,  C07D405/12 ,  C07D405/14 ,  C07D407/12 ,  C07D409/12 ,  C07D413/10 ,  C07D413/12 ,  C07D413/14 ,  C07D417/10 ,  C07D453/02 ,  C07D471/10 ,  C07D487/04 ,  C07D491/107 ,  C07D498/08 ,  C07B2200/05

Abstract: The present disclosure provides novel pladienolide compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancer, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are methods of treating cancers by administering at least one compound disclosed herein and at least one additional therapy.